Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2016-01-01
2019-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of Lysine Requirements in Pregnancy
NCT01776931
Determination of Protein Requirements in Pregnancy
NCT01784198
Tryptophan Requirements During Pregnancy
NCT06519071
Determination of Glycine Requirement in Pregnancy
NCT02149953
Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)
NCT00065299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Current dietary intake recommendations for phenylalanine are based on factorial (mathematical) calculations and do not account for requirement differences between early and late pregnancy. Static recommendations throughout all stages of pregnancy are not appropriate because of the multitude of adaptations the human body goes through during gestation. Whether phenylalanine requirements differ between different stages of gestation is unknown. In addition, phenylalanine is the precursor for tyrosine, which is a conditionally indispensable amino acid. Together they are referred to as the aromatic amino acids. The DRI gives a recommendation for total aromatic amino acids (TAA, phenylalanine + tyrosine) of 36 mg/kg/d during pregnancy. Since this study is the first interested in phenylalanine requirements during pregnancy, the investigators will determine the phenylalanine requirements in the presence of excess tyrosine (61 mg/kg/d) during pregnancy, similar to earlier studies.
The investigators will recruit healthy pregnant women aged 20 to 40 in their 13th-19th week of gestation or 33rd to 39th week of gestation. Once they get in contact with the lab, an initial visit (pre-study) will take place. Here, the participants will be measured for their eligibility and taken through the consent form. They have to participate in a pre-study for each stage of pregnancy, if they wish to participate in both stages. If they meet all the criteria and agree to participate, they will return for up to two study days per stage of 8 hours each. Therefore, if they are recruited during late pregnancy they are only able to participate in two study days in total. During these study days they will be fed protein shakes containing the stable isotope, and then oxidation of this isotope will be measured to determine a breakpoint (requirement) of phenylalanine. Breath samples, urine samples, and a small blood sample will be taken during the study day.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: phenylalanine intake
Dietary supplement: phenylalanine intake
Phenylalanine intake
Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phenylalanine intake
Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* under the age of forty
* in overall good health
* pregnant with a single child
Exclusion Criteria
* Be over the age of forty
* Be pregnant with more than one child
* Have a history of cardiovascular disease, endocrine disorders, or metabolic disorders
* Have recently lost a substantial amount of weight
* Delivered a baby in the last 18 months
* Be substance dependent
* Be allergic to eggs
* Have severe nausea through the pregnancy
* Have gestational diabetes
* Have a history of spontaneous abortions
* Have had an unhealthy pre-pregnancy body mass index
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rajavel Elango, PhD
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rajavel Elango, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BC Children's Hospital Research Institute, University of British Columbia
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ennis MA, Rasmussen BF, Lim K, Ball RO, Pencharz PB, Courtney-Martin G, Elango R. Dietary phenylalanine requirements during early and late gestation in healthy pregnant women. Am J Clin Nutr. 2020 Feb 1;111(2):351-359. doi: 10.1093/ajcn/nqz288.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H15-02558
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.